Meier W, Stieber P, Fateh-Moghadam A, Eiermann W, Hepp H
Department of Obstetrics and Gynecology, Klinikum Grosshadern, University of Munich, West Germany.
Eur J Cancer Clin Oncol. 1987 Jun;23(6):713-7. doi: 10.1016/0277-5379(87)90267-7.
CA-125 is an antigenic determinant that can be demonstrated in the majority of epithelial ovarian carcinomas. It can be measured in the serum with a radioimmunoassay by means of a monoclonal antibody. The tumor marker has a low specificity but high sensitivity for ovarian cancer, especially for serous cystadenocarcinoma. In our investigation we were interested in particular in the correlation between CA-125 and the histological findings at second-look operation. In 22 patients, second-look was performed after 6 cycles of chemotherapy, in 16 patients active tumor was demonstrated. In 6 patients with negative CA-125 values, residual tumor less than 1 cm was demonstrated. In order to verify a complete remission, a second-look operation has to be performed. No false-positive CA-125 levels were found. In all patients with elevated CA-125 serum values, residual tumor was histologically confirmed at second look.
CA - 125是一种抗原决定簇，可在大多数上皮性卵巢癌中检测到。它可以通过单克隆抗体采用放射免疫测定法在血清中进行检测。该肿瘤标志物对卵巢癌的特异性低但敏感性高，尤其对浆液性囊腺癌。在我们的研究中，我们特别关注CA - 125与二次探查手术时组织学结果之间的相关性。22例患者在化疗6个周期后进行了二次探查，其中16例显示有活动性肿瘤。在6例CA - 125值为阴性的患者中，发现残留肿瘤小于1厘米。为了证实完全缓解，必须进行二次探查手术。未发现CA - 125水平出现假阳性。在所有CA - 125血清值升高的患者中，二次探查时经组织学证实有残留肿瘤。
